No matches

Educational Resources

Barrier disruption in AD and the development of environmental and food allergies

Can advanced systemic therapies modify pathomechanisms in AD?

Dermatology

5 min

expert video

Can advanced systemic therapies modify pathomechanisms in AD?

Current systemic therapies have been shown to induce remission in a subset of AD patients

Dermatology

5 min

expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

Rhinology

9 min

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

Rhinology

9 min

expert video

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

Pulmonology

5 min

interactivity

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Dermatology

2 min

expert video

ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

Gastroenterology

5 min

Infographic

Adaptive Behaviors in EoE Infographic

Gastroenterology

10 min

expert video

Assessing EoE: Using Endoscopic Features to Assess Disease Status

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region

Educational Resources

Barrier disruption in AD and the development of environmental and food allergies

Can advanced systemic therapies modify pathomechanisms in AD?

Current systemic therapies have been shown to induce remission in a subset of AD patients

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Most Burdensome Symptoms Rated by PN Patients

ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

Adaptive Behaviors in EoE Infographic

Assessing EoE: Using Endoscopic Features to Assess Disease Status

Educational Resources

Barrier disruption in AD and the development of environmental and food allergies

Can advanced systemic therapies modify pathomechanisms in AD?

Current systemic therapies have been shown to induce remission in a subset of AD patients

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Most Burdensome Symptoms Rated by PN Patients

ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

Adaptive Behaviors in EoE Infographic

Assessing EoE: Using Endoscopic Features to Assess Disease Status